Protocol - Pre-transfusion Antibody Testing
This protocol includes two items from the Sickle Cell Disease and Cardiovascular Risk—Red Cell Exchange Trial (SCD CARRE) that use existing medical records to capture the results of a red blood cell (RBC) antibody screen and direct antiglobulin test (DAT).
Date of sample
(If different from above)
1 RBC Antibody Screen
[ ] Negative
[ ] Positive
2 Direct Antiglobulin
[ ] Negative
[ ] Positive
Personnel and Training Required
This information should be abstracted by someone conversant in hematology.
|Specialized requirements for biospecimen collection||No|
|Average time of greater than 15 minutes in an unaffected individual||No|
Mode of Administration
Medical record abstraction
This form is to be completed by designated personnel for all adverse transfusion reactions.
The Sickle Cell Disease Curative Therapies Working Group selected questions from the Sickle Cell Disease and Cardiovascular Risk—Red Cell Exchange (SCD-CARRE) as the best standardized methodology for collecting data on pre-transfusion antibody testing.
|caDSR Common Data Elements (CDE)||Laboratory Procedure Red Blood Cell Antibody Test Result||7765231||CDE Browser|
|caDSR Common Data Elements (CDE)||Laboratory Procedure Direct Antiglobulin Antibody Test Result||7765235||CDE Browser|
Process and Review
Protocol Name from Source
Sickle Cell Disease and Cardiovascular Risk—Red Cell Exchange Trial (SCD CARRE)
National Heart, Lung, and Blood Institute. (2020). Sickle Cell Disease and CardiovAscular Risk—Red Cell Exchange (Version 1.0) [Laboratory evaluation].
Chou, S T., Alsawas, M., Fasano, R. M., Field, J. J., Hendrickson, J. E., Howard, J., Kameka, M., Kwiatkowski, J. L., Pirenne, F., Shi, P. A., Stowell, S. R., Thein, S. L., Westhoff, C. M., Wong, T. E., & Akl, E. A. (2020). American Society of Hematology 2020 guidelines for sickle cell disease: Transfusion support. Blood Advances, 4(2), 327–355.
|Variable Name||Variable ID||Variable Description||dbGaP Mapping|
Pre-transfusion Antibody Reporting
August 16, 2021
This measure is used to record the presence or absence of red cell antibodies.
The transfusion recipient can mount an immune response to donor red blood cells, which can result in a hemolytic transfusion reaction, shock, kidney failure, circulatory system collapse, and death.
Sickle cell disease, SCD, transfusion, antibody, direct antiglobulin test, DAT
|Protocol ID||Protocol Name|
|850901||Pre-transfusion Antibody Testing|
There are no publications listed for this protocol.